Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.55 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24165013 | 1.00 | EGFR (0.55) | EGFRCSF1RPIM1PIM2CNR2 | |
| SCHEMBL25394855 | 0.77 | EGFR (0.74) | EGFRCSF1RMAPTMEN1ALDH1A1 | |
| SCHEMBL25394740 | 0.73 | MAPT (0.75) | EGFRCSF1RMAPTMEN1ALDH1A1 | |
| SCHEMBL9141810 | 0.73 | DRD4 (0.54) | ALDH1A1KMT2A | |
| SCHEMBL9140781 | 0.69 | SLC6A12 (0.58) | MEN1KMT2A | |
| SCHEMBL9140774 | 0.69 | KMT2A (0.59) | MEN1ALDH1A1KMT2A | |
| SCHEMBL29385390 | 0.68 | TNF (0.71) | — | |
| SCHEMBL24164971 | 0.68 | TNF (0.71) | — | |
| SCHEMBL24164969 | 0.68 | TNF (0.71) | — | |
| SCHEMBL30526900 | 0.68 | TNF (0.71) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265089-A1 | QUINOLINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC | 2023-08-24 | — | — | US | disclosed |
| US-20230265089-A1 | QUINOLINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC | 2023-08-24 | — | — | US | disclosed |
| WO-2022005494-A1 | QUINOLINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC (US) | 2022-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265089-A1 | QUINOLINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS, AND METHODS OF USE THEREOF | NQO2, STAT6, TPMT | EGFR 4713/4885CSF1R 2395/4885PIM1 4547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.